AMUNIX
Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. By delivering breakthrough therapies that can safely harness the immune system, it aims to conquer cancer and save lives. Its pipeline products are based on its proprietary XTEN half-life extension, XDC drug-conjugate d... elivery, and ProTIA pro-drug, bispecific T cell engager platform and have ongoing collaborations with biopharma corporations harnessing these delivery technologies over a wide range of therapeutic areas, delivering improved pharmaceutical technologies. Amunix was founded in 2006 and is headquartered in Mountain View, California.
AMUNIX
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
2006-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.amunix.com
Total Employee:
51+
Status:
Active
Contact:
650-428-1800
Email Addresses:
[email protected]
Total Funding:
190 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Universal Analytics Apache Microsoft Exchange Online Office 365 Mail
Similar Organizations
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.
Genocea Biosciences
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies.
GigaGen
GigaGen specialized in the early discovery and development of recombinant biotherapeutic medicines.
Gossamer Bio
Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series B - Amunix
Clough Capital Partners
Clough Capital Partners investment in Series B - Amunix
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series B - Amunix
Polaris Partners
Polaris Partners investment in Series B - Amunix
Franklin Templeton Investments
Franklin Templeton Investments investment in Series B - Amunix
CaaS Capital Management
CaaS Capital Management investment in Series B - Amunix
BlackRock
BlackRock investment in Series B - Amunix
ArrowMark Partners
ArrowMark Partners investment in Series B - Amunix
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Amunix
Longitude Capital
Longitude Capital investment in Series B - Amunix
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2013-10-08 | Versartis | Amunix investment in Series D - Versartis | 20 M USD |
Official Site Inspections
http://www.amunix.com Semrush global rank: 3.25 M Semrush visits lastest month: 5.1 K
- Host name: ewhserver1302.edgewebhosting.net
- IP address: 69.63.140.80
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Amunix" on Search Engine
XPAT® | Pro-XTEN Platform | T Cell Engagers | Amunix …
Amunix is an immuno-oncology company leveraging Pro-XTEN technology platform to discover and develop transformative therapies for patients with cancer.See details»
Management and Board of Directors for Amunix Pharmaceuticals
The Amunix site focuses on immuno-oncology, leveraging our proprietary, clinically validated PRO-XTEN™ technology platform to discover and develop transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer.See details»
Sanofi to acquire Amunix immuno-oncology pipeline with next …
Dec 21, 2004 Amunix Pharmaceuticals is an immuno-oncology company focused on designing and developing masked T cell engagers and cytokines to bring the promise of these potent immune-activating biotherapeutics to patients with cancers.See details»
Sanofi completes acquisition of Amunix
Feb 8, 2013 Sanofi announced today the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine therapies. The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics.See details»
Amunix - Crunchbase Company Profile & Funding
Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers.See details»
Sanofi to acquire Amunix immuno-oncology pipeline with next …
Dec 21, 2021 Amunix’s proprietary XTEN ® masks and cleavable linkers are a next-generation protein engineering approach that allows biologics to circulate in “stealth” mode, becoming active preferentially in...See details»
Press Release | Amunix Pharmaceuticals
Amunix Pharmaceuticals, based in South San Francisco, CA, is focused on developing masked T cell engagers and cytokines to bring the promise of these potent immune-activating biotherapeutics to patients with solid tumor cancers.See details»
Sanofi’s $1B Amunix acquisition aims for targeted, safer T cell ...
Dec 21, 2021 In acquiring Amunix, Sanofi becomes the latest big pharmaceutical company to strike a deal to gain access to technology that improves the safety and efficacy of T cell engager cancer therapies.See details»
Sanofi to acquire immuno-oncology firm Amunix for $1bn
Dec 22, 2021 Amunix designs and develops masked T cell engagers (TCE) and cytokines to deliver potential immune-activating biotherapeutics to cancer patients utilising its XPAT, XPAC, XTEN and Pro-XTEN platforms. On closing of the acquisition, Sanofi will own various TCEs, cytokine therapies as well as platforms of Amunix.See details»
Amunix Raises $117 Million Series B Financing to Fund ... - Yahoo Finance
Mar 4, 2021 About Amunix Pharmaceuticals Amunix Pharmaceuticals, based in South San Francisco, CA, is focused on developing masked T cell engagers and cytokines to bring the promise of these potent...See details»
Sanofi to acquire Amunix immuno-oncology pipeline - PharmaLive
Dec 21, 2021 Paris-based Sanofi is buying South San Francisco’s Amunix Pharmaceuticals in a deal topping $1.225 billion. Amunix focuses on immuno-oncology with a proprietary XEN and universal protease-releasable …See details»
Amunix unveils next-generation immuno- oncologic cancer
Amunix unveils next-generation immuno-oncologic cancer therapy platform. A novel immunotherapy with extended serum half-life in a prodrug delivery format holds promise for overcoming the...See details»
The latest news and press releases from Amunix Pharmaceuticals
May 13, 2021 The latest news from Amunix, an immuno-oncology company leveraging Pro-XTEN technology platform to discover and develop transformative therapies for patients with cancer.See details»
Sanofi in $1 billion deal to buy U.S.-based Amunix Pharma - Yahoo Finance
Dec 21, 2021 PARIS (Reuters) - Drugmaker Sanofi SA will buy Amunix Pharmaceuticals Inc for an upfront payment of about $1 billion, marking the latest acquisition by the French drugmaker in the U.S....See details»
Sanofi acquires Amunix - 2021-12-20 - Crunchbase
Dec 20, 2021 Overview. Acquired Organization: Amunix Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. Acquiring Organization: Sanofi Sanofi is a healthcare company that provides treatments and the protection of life-saving vaccines. Announced Date Dec 20, 2021.See details»
Sanofi completes acquisition of Amunix - GlobeNewswire
Feb 8, 2022 Sanofi announced today the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine therapies. The acquisition also provides...See details»
Amunix - Funding, Financials, Valuation & Investors - Crunchbase
Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics.See details»
Press Release | Amunix Pharmaceuticals
Amunix is advancing its lead development candidate, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, toward the clinic, and has several discovery programs underway. By delivering breakthrough therapies that can safely harness the immune system, we aim to conquer cancer and save lives.See details»
Volker Schellenberger - Co-Founder, President, and CTO @ Amunix ...
Amunix. Location Palo Alto, California, United States. Regions San Francisco Bay Area, Silicon Valley, West Coast. Gender Male. Investor Type Investment Partner. LinkedIn View on LinkedIn. Volker has 18 years of industry experience in protein engineering and …See details»
SAR 446309 - AdisInsight - Springer
Aug 4, 2022 Drug Profile. SAR 446309. Alternative Names: AMX-818; HER2-XPAT - Amunix; SAR-446309. Latest Information Update: 04 Aug 2022. Price : $50 * Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according to local VAT and billing address.See details»